SBI-0206965

• CAT Number: I002431
• CAS Number: 1884220-36-3
• Molecular Formula: C21H21BrN4O5
• Molecular Weight: 489.3
• Purity: ≥95%
• Synonyms: (Z)-2-((5-bromo-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)oxy)-N-methylbenzimidic acid
• Target: Autophagy
• Solubility: 10 mM in DMSO
• Storage: -20°C
• IC50: 108nM/711 nM
• IUPAC Name: 2-[5-bromo-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]oxy-N-methylbenzamide
• InChI: InChI=1S/C21H21BrN4O5/c1-23-19(27)13-7-5-6-8-15(13)31-20-14(22)11-24-21(26-20)25-12-9-16(28-2)18(30-4)17(10-12)29-3/h5-11H,1-4H3,(H,23,27)(H,24,25,26)
• InChIKey: NEXGBSJERNQRSV-UHFFFAOYSA-N
• SMILES: CNC(=O)C1=CC=CC=C1OC2=NC(=NC=C2Br)NC3=CC(=C(C(=C3)OC)OC)OC

SBI-0206965（Cat No.:I002431） is a potent and highly selective inhibitor of the autophagy kinase ULK1, with an IC50 of 108 nM. It exhibits 7-fold greater selectivity towards ULK1 compared to ULK2. By inhibiting ULK1, SBI-0206965 effectively suppresses the autophagic process. Furthermore, it has been shown to enhance apoptosis in human glioblastoma and lung cancer cells. These findings suggest that SBI-0206965 holds promise as a potential therapeutic agent for the treatment of these cancer types by targeting autophagy and promoting apoptosis.

Reference

[1]. Egan DF, et al. Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates. Mol Cell. 2015 Jul 16;59(2):285-297.